- Conditions
- Age-Related (Dry) Macular Degeneration
- Interventions
- AC Tap (anterior chamber paracenthesis)
- Procedure
- Lead sponsor
- ClinOmicsAI
- Network
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Erie, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 150
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Geographic Atrophy, Age-Related Macular Degeneration
- Interventions
- OcuMet Beacon
- Device
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Geographic Atrophy
- Interventions
- Pegcetacoplan, Sham Procedure
- Drug · Other
- Lead sponsor
- Apellis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 246 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 35
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Beverly Hills, California + 31 more
- Conditions
- Age-related Macular Degeneration (AMD), Geographic Atrophy (GA)
- Interventions
- Pozelimab, Cemdisiran, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 975 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2033
- U.S. locations
- 158
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 125 more
- Conditions
- Macular Degeneration, Geographic Atrophy
- Interventions
- IONIS-FB-LRx, Placebo
- Drug
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 332 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 55
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Beverly Hills, California + 47 more
- Conditions
- Age Related Macular Degeneration (AMD)
- Interventions
- GT005
- Genetic
- Lead sponsor
- Gyroscope Therapeutics Limited
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 22
- States / cities
- Poway, California • Durango, Colorado • Gainesville, Florida + 18 more
- Conditions
- Age-Related Macular Degeneration, Geographic Atrophy, Diabetic Retinopathy, Macular Edema, Retinal Vein Occlusion, Central Serous Retinopathy, Pattern Dystrophy of Macula, Epiretinal Membrane, Macular Hole
- Interventions
- Not listed
- Lead sponsor
- Optos, PLC
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 3
- States / cities
- Fort Lauderdale, Florida • Baltimore, Maryland • McAllen, Texas
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Eculizumab, Saline
- Drug
- Lead sponsor
- Philip J. Rosenfeld, MD, PhD
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Age-Related Maculopathy, Age-Related Maculopathies, Eye Diseases, Retinal Degeneration, Macular Degeneration
- Interventions
- RN6G, Placebo
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 24
- States / cities
- Campbell, California • Los Gatos, California • San Jose, California + 7 more
- Conditions
- Age-related Macular Degeneration
- Interventions
- Diagnostics
- Diagnostic Test
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Dry Age Related Macular Degeneration
- Interventions
- MA09-hRPE
- Biological
- Lead sponsor
- Astellas Institute for Regenerative Medicine
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Miami, Florida • Boston, Massachusetts + 1 more
- Conditions
- Dry Age-Related Macular Degeneration, Geographic Atrophy
- Interventions
- iPSC-derived RPE/PLGA transplantation
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 55 Years to 95 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Bethesda, Maryland
- Conditions
- Geographic Atrophy Secondary to Age-related Macular Degeneration
- Interventions
- CTx001
- Genetic
- Lead sponsor
- Complement Therapeutics
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 4
- States / cities
- Carmel, Indiana • Reno, Nevada • Dallas, Texas + 1 more
- Conditions
- Geographic Atrophy
- Interventions
- PEGCETACOPLAN (APL-2)
- Drug
- Lead sponsor
- Apellis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 5
- States / cities
- Bakersfield, California • Beverly Hills, California • Encino, California + 2 more
- Conditions
- Dry Age-related Macular Degeneration, Geographic Atrophy
- Interventions
- ACU-4429, Matching placebo
- Drug
- Lead sponsor
- Kubota Vision Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Daytona Beach, Florida + 9 more
- Conditions
- Age-related Macular Degeneration
- Interventions
- VMS diary booklet, Standard of Care
- Behavioral
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- Not listed
- Enrollment
- 324 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Dry Age-related Macular Degeneration, Geographic Atrophy, Retinal Disease, Macular Degeneration, Macular Atrophy, Retinal Degeneration, Eye Diseases
- Interventions
- Not listed
- Lead sponsor
- Complement Therapeutics
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 250 participants
- Timeline
- 2023 – 2027
- U.S. locations
- 10
- States / cities
- Glendale, California • Mountain View, California • Carmel, Indiana + 7 more
- Conditions
- Age-related Macular Degeneration
- Interventions
- Brolucizumab 6 mg, Aflibercept 2 mg
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 734 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Huntington Beach, California • Loma Linda, California + 20 more
- Conditions
- Stargardts, Retinitis Pigmentosa, Age-related Macular Degeneration, Choroideremia, Geographic Atrophy
- Interventions
- Retinal imaging
- Procedure
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 7 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2031
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Macular Degeneration, Age-Related, Geographic Atrophy
- Interventions
- Galegenimab, Sham Control
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 372 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 72
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 65 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- alpha lipoic acid, Placebo
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2019
- U.S. locations
- 5
- States / cities
- Iowa City, Iowa • Teaneck, New Jersey • Eugene, Oregon + 2 more
- Conditions
- Visual Acuity, Geographic Atrophy, Macular Degeneration
- Interventions
- CNTO 2476 3.0 x 10^5 cells, Subretinal Delivery System
- Drug · Device
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 8
- States / cities
- Arcadia, California • Chicago, Illinois • Lexington, Kentucky + 5 more
- Conditions
- Age-Related (Dry) Macular Degeneration
- Interventions
- Retina imaging device (MSI-120) and AI (DeepMSI AI)
- Device
- Lead sponsor
- AI-Spectral
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Woodbridge, New Jersey
- Conditions
- Age-Related Macular Degeneration, Geographic Atrophy
- Interventions
- Not listed
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- Houston, Texas